Selina Kim

Selina Kim is a Senior Life Science Analyst at Airfinity, where they lead a team focused on delivering predictive insights in the respiratory syncytial virus (RSV) field. Previously, Selina conducted significant analysis on COVID-19 vaccine uptake that was published in The Economist. They have also held roles as an Epidemiologist, leading epidemiological analysis and product development in influenza and RSV. Selina co-founded the fastest growing student campaign at Imperial College London and completed a Bachelor of Science in Biology with First Class Honours and a Master of Science in Epidemiology.